Supplementary Table 3.
Assessment of Metabolic Syndrome at Baseline and Repeat Assessment in a Subset of Participants
| Metabolic syndrome status | N at baseline | Of which unchanged at repeat assessmenta n (%) |
|---|---|---|
| Harmonized | ||
| Absent | 11,036 | 8635 (78.2) |
| Prevalent | 4116 | 3275 (80.0) |
| Total | 15,152 | 11,910 (78.6) |
| NCEP-ATPIII | ||
| Absent | 11,450 | 9031 (78.9) |
| Prevalent | 3702 | 2892 (78.1) |
| Total | 15,152 | 11,923 (78.7) |
| IDF 2005 | ||
| Absent | 11,831 | 9999 (84.5) |
| Prevalent | 3321 | 2555 (77.0) |
| Total | 15,152 | 12,554 (82.9) |
IDF 2005, International Diabetes Federation 2005; NCEP-ATPIII, National Cholesterol Education Program – Adult Treatment Panel III.
a
After a median duration of 4.3 years.